Using the percentage of tumor cells positive for PRL-3 among the four subtypes, we determined that PRL-3 expression was significantly higher in TNBC versus luminal A breast cancer (p = 0.008, Figure 7B). The gene discussed is PTP4A3; the disease is breast carcinoma.